GZMB and neoplasm: Functional indicator analysis demonstrated that CD25-expressing (CD25+) and granzyme B-expressing (GzmB+) CD8+ T and NK cells in tumor grafts treated with αNKG2A-N215 (12 μg) were also 2–4 times more than those in tumor grafts treated with αNKG2A + N215 (12 μg) (Figures 5(E,F,G) and S8).